- JP-listed companies
- Balance sheet
【JP:206A】Balance sheet
Market cap
¥6.7B
P/E ratio
PRISM BioLab develops new drugs that target hard-to-reach protein interactions inside cells, partnering with major pharmaceutical companies like Eisai.
| 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Cash and cash equivalents | - | 1,688 | 1,134 | 4,392 | 2,916 |
| Total cash & short-term investments | - | 1,688 | 1,134 | 4,392 | 2,916 |
| Total current assets | - | 1,732 | 1,198 | 4,483 | 3,039 |
| Property, plant and equipment, net | - | - | - | - | - |
| Total non-current assets | - | 8 | 14 | 45 | 47 |
| Total assets | - | 1,740 | 1,211 | 4,529 | 3,086 |
| Total current liabilities | - | 65 | 63 | 1,020 | 370 |
| Total non-current liabilities | - | 0 | 0 | 6 | 7 |
| Total liabilities | - | 65 | 63 | 1,026 | 377 |
| Retained earnings | - | 34 | -493 | -1,543 | -2,376 |
| Stockholders' equity | 1,093 | 1,675 | 1,148 | 3,503 | 2,709 |